SCHEMBL4924040

SCHEMBL4924040

COc1ccc(Nc2c(NCc3cccc(O)c3)c(=O)c2=O)cc1-n1ccnc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 7/20 0.42
ROCK1 Q13464 7/20 0.42
PRKACA P17612 6/20 0.42
RPS6KB1 P23443 6/20 0.42
RPS6KA3 P51812 6/20 0.42
CDC42BPA Q5VT25 6/20 0.42
AURKB Q96GD4 6/20 0.42
PRKG1 Q13976 6/20 0.42
GSK3A P49840 6/20 0.42
ROCK2 O75116 5/20 0.42
CLK4 Q9HAZ1 5/20 0.42
CHEK2 O96017 5/20 0.42
PKN2 Q16513 5/20 0.42
HIPK4 Q8NE63 5/20 0.42
CSNK1G3 Q9Y6M4 5/20 0.42
AKT1 P31749 4/20 0.42
CHEK1 O14757 4/20 0.42
MKNK2 Q9HBH9 4/20 0.42
SGK2 Q9HBY8 4/20 0.42
AKT2 P31751 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4920526 0.88 ROCK1 (0.45) GSK3BROCK1PRKACARPS6KB1RPS6KA3
SCHEMBL4925930 0.76 EGFR (0.44) GSK3BROCK1PRKACARPS6KB1RPS6KA3
SCHEMBL4927504 0.74 GSK3B (0.43) GSK3BROCK1PRKACARPS6KB1RPS6KA3
SCHEMBL4906887 0.72 MAPKAPK2 (0.54) GSK3BROCK1PRKACARPS6KB1RPS6KA3
SCHEMBL4917069 0.71 EGFR (0.50) GSK3BROCK1PRKACARPS6KB1RPS6KA3
SCHEMBL4900237 0.71 NPC1 (0.50) GSK3BROCK1PRKACARPS6KB1RPS6KA3
SCHEMBL4902096 0.71 NOTUM (0.43) GSK3BROCK1PRKACARPS6KB1RPS6KA3
SCHEMBL4897396 0.70 GSK3B (0.45) GSK3BROCK1PRKACARPS6KB1RPS6KA3
SCHEMBL4925124 0.70 MAPKAPK2 (0.53) GSK3BROCK1PRKACARPS6KB1RPS6KA3
SCHEMBL4911196 0.70 MEN1 (0.55) GSK3BROCK1PRKACARPS6KB1RPS6KA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312244-A1 Squaric Acid Derivatives as Protein Kinase Inhibitors MERCK PATENT GMBH (DE) 2008-12-18 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312244-A1 Squaric Acid Derivatives as Protein Kinase Inhibitors CHEK1, CHEK2, SIK1 GSK3B 164/4885ROCK1 470/4885PRKACA 903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.